Org. age Ohio . 711 - The Ohio State University

36
College Research Day
On May 11, 2006 the College hosted an inaugural event, The College of Pharmacy
Research Day 2006. Research Day 2006 is one of the many new College activities that
promote interdisciplinary discussion and interactions for knowledge exchange relating to
drug discovery, development and therapeutics. The Patil Symposium was held in the
afternoon in honor of emeritus professor, Dr. Popat Patil, Division of Pharmacology, who
retired June 2005. The event recognized Dr. Patil’s distinguished research career and
featured lectures from distinguished alumni who studied under Dr. Patil. College faculty
and students presented 70 posters showcasing their research efforts.
College Distinguished Lecture Series
The Distinguished Lecture Series is designed to bring outstanding pharmaceutical
scientists and educators to the College of Pharmacy to present a lecture of current topical
interest to students and faculty. The lectures are general and aim to inform the College
community at large. The lecturers also interact with faculty and students in their
disciplinary area of interest. Lecturers are nominated by division faculty through the
division chairs. The nominations are reviewed by the Graduate and Research Committee,
which recommends lecturers to the Executive Committee for its approval.
Speakers for the 2005-06 Distinguished Lecture Series were:
Dr. Mansukh C. Wani, Research Triangle Institute
“Plant-Derived Anticancer Agents, Taxol and Camptothecin: From Bench to Bedside”.
Dr. Wani, in partnership with the late Dr. Monroe Wall, discovered two compounds,
camptothecin and Taxol, which since 1992 have been instrumental in the fight against
cancer and whose derivatives today represent nearly one-third of all anti-cancer
medications on the market.
Dr. Neal Castagnoli, Peters Professor of Chemistry, Virginia Polytechnic Institute and
State University
"Mechanistic Studies on the Enzyme-Catalyzed Oxidations of Amines", Dr. Castagnoli is
an expert in molecular mechanisms of drug metabolism and pharmacological
processes including monoamine oxidase and cytochrome P-450 and a noted mass
spectrometrist. His research has been particularly noted for nicotine related
neurotoxicity and neuroprotection and areas that relate to Parkinson's Disease. He
was special assistant to the Commissioner of the Food and Drug Administration and on
editorial boards of reputable journals including the Journal of Pharmacology and
Experimental Therapeutics.
Dr. Daria Hazuda, Vice President, Virus and Cell Biology Research, Merck Research
Laboratories
“HIV-1 Integrase Inhibitors: Past, Present and Future?”. Dr. Hazuda's scientific
interests focus on drugs that target HIV/AIDS and Alzheimer's Disease. Internationally
renowned for her studies on HIV integration, Dr. Hazuda is particularly credited for
discovery of the first authentic HIV integrase inhibitors, which have recently
successfully completed Phase II clinical trials.
Dr. J. Steven Leeder, Marion Merrell Dow Endowed Chair in Pediatric
Pharmacogenomics, The University of Missouri-Kansas City
"Prenatal Pharmacogenetics and the Promise of Developmental Pharmacogenomics".
Dr. Leeder conducts a renowned research program in pharmacogenetics and
pharmacogenomics, with regard to the ontogeny of drug metabolism in children.
Specific emphasis is placed on pharmacogenetic determinants of drug-induced birth
defects and adverse drug reactions in children.